alexa
Reach Us +44-1647-403003
Hipec in Ovarian Cancer. Why is it Still the Ugly Duckling of Intraperitoneal Therapy? | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Letter to Editor

Hipec in Ovarian Cancer. Why is it Still the Ugly Duckling of Intraperitoneal Therapy?

Pedro Antonio Cascales Campos*, Jose Gil, Pablo Munoz-Ramon and Pascual Parrilla

Hospital Universitario Virgen de la Arrixaca, Department of Surgery, Murcia, Spain

Corresponding Author:
Cascales PAC
Hospital Universitario Virgen de la Arrixaca
Department of Surgery, Ctra. Madrid-Cartagena
s/n, 30120 El Palmar, Murcia, Spain
Tel: +34968369500
E-mail: [email protected]

Received Date: December 21, 2015; Accepted Date: February 10, 2016; Accepted Date: February 12, 2016

Citation: Cascales Campos PA, Gil J, Munoz-Ramon P, Parrilla P (2016) Hipec in Ovarian Cancer. Why is it Still the Ugly Duckling of Intraperitoneal Therapy? J Cancer Sci Ther 08:030. doi: 10.4172/1948-5956.1000383

Copyright: © 2016 Cascales Campos PA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

What kind of intraperitoneal therapy would be recommend for our mother, sister, wife or daughter if she was diagnosed with advanced ovarian cancer and if we were in the office of an experienced surgeon able to achieve an optimal resection or, even better, a complete resection of her disease? If one was a surgeon who believed in postoperative systemic chemotherapy, one’s argument would be based on the results of the study GOG 172 (which coincided with a clinical alert from the NCI of the United States in favor of this modality of intraperitoneal treatment after optimal surgery in patients with ovarian cancer)

Top